explore -WSS

explore

author：explore 2025-09-30 12:11:11 - browse：29654

Electrocardiogram in the shape of the United States map — Adobe

The market for artificial intelligence in health care is about as transparent as a brick wall. New tools achieve impressive results in published studies. But it is often difficult to compare them head to head with similar products, or tell whether they will work on different kinds of patients.

A new company is promising to change that — if it can convince AI developers to expose their products to more rigorous testing.

Called Dandelion Health, the New York-based firm is launching a first-of-its-kind public service to evaluate AI products on independent data designed to root out weaknesses and reveal bias. The company said Wednesday its initial pilot program, to begin next month, will focus on testing algorithms that use electrocardiograms to predict heart conditions.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： The Harvard botanist who searched for psychedelics in the Amazon

WSS

Involuntary treatment for addiction doesn't work

6 phony surgeries that take placebo to the extreme

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

Wikipedia

explore

focus

Medical leaders decry Supreme Court decision on affirmative action

Does aspartame cause cancer? What new WHO guidance says

Medical records are filled with copy

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

Novavax promises a turnaround & Lilly roils the obesity market

Community Health Systems hospitals under DOJ investigation

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Medicare inequities exacerbate Puerto Rico’s health disparities

BioMarin wins approval for gene therapy to treat hemophilia A

Who gets to use the title 'doctor'?

focus

Europe sees delivery challenges ahead on Alzheimer's therapies

Congress likely to miss an opportunity to fix drug shortages issue

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Congress likely to miss an opportunity to fix drug shortages issue

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Obesity drugs seen as possible treatment for liver disease MASH

focus

explore

knowledge

knowledge